Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Axatilimab Combined With Decitabine/Venetoclax for the Treatment of TP53-mutated/Deleted AML Patients

NCT07511062 is registered in ClinicalTrials.gov with Northside Hospital, Inc. as lead sponsor.

NCT NCT07511062
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07511062 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Axatilimab Combined With Decitabine/Venetoclax for the Treatment of TP53-mutated/Deleted AML Patients
Lead sponsor
Northside Hospital, Inc.
Phase
Phase 1
Overall status
Not yet recruiting
Start date
August 1, 2026
Completion date
August 1, 2030
Enrollment
32 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia, tp53 gene mutation